EP0679083A1 - Prävention und behandlung von sepsis - Google Patents

Prävention und behandlung von sepsis

Info

Publication number
EP0679083A1
EP0679083A1 EP94909422A EP94909422A EP0679083A1 EP 0679083 A1 EP0679083 A1 EP 0679083A1 EP 94909422 A EP94909422 A EP 94909422A EP 94909422 A EP94909422 A EP 94909422A EP 0679083 A1 EP0679083 A1 EP 0679083A1
Authority
EP
European Patent Office
Prior art keywords
conjugate
antibiotic
igg
pmb
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909422A
Other languages
English (en)
French (fr)
Other versions
EP0679083A4 (de
Inventor
Sean B. Carroll
Joseph R. Firca
Charles S.G. Pugh
Nisha Vikas Padhye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Ophidian Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/169,701 external-priority patent/US5545721A/en
Application filed by Ophidian Pharmaceuticals Inc filed Critical Ophidian Pharmaceuticals Inc
Publication of EP0679083A1 publication Critical patent/EP0679083A1/de
Publication of EP0679083A4 publication Critical patent/EP0679083A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58—Bacitracins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
EP94909422A 1992-12-21 1993-12-20 Prävention und behandlung von sepsis. Withdrawn EP0679083A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99538892A 1992-12-21 1992-12-21
US995388 1992-12-21
US16406793A 1993-12-08 1993-12-08
US164067 1993-12-08
US08/169,701 US5545721A (en) 1992-12-21 1993-12-17 Conjugates for the prevention and treatment of sepsis
US169701 1993-12-17
PCT/US1993/012381 WO1994014437A1 (en) 1992-12-21 1993-12-20 Prevention and treatment of sepsis

Publications (2)

Publication Number Publication Date
EP0679083A1 true EP0679083A1 (de) 1995-11-02
EP0679083A4 EP0679083A4 (de) 1999-03-24

Family

ID=27388964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909422A Withdrawn EP0679083A4 (de) 1992-12-21 1993-12-20 Prävention und behandlung von sepsis.

Country Status (5)

Country Link
EP (1) EP0679083A4 (de)
JP (1) JPH08504824A (de)
AU (1) AU693433B2 (de)
CA (1) CA2151386A1 (de)
WO (1) WO1994014437A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
JP2009513572A (ja) * 2005-09-28 2009-04-02 ベントリア バイオサイエンス 腸管障害及び／又は下痢用の経口組成物
WO2023080797A1 (en) * 2021-11-05 2023-05-11 Koru Diagnostics Limited Method for detecting pathogenic gram-negative microorganisms and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (de) * 1982-03-09 1983-09-14 Cytogen Corporation Antikörper-Verbindungen
EP0122132A2 (de) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Antikrebsmittel
WO1989004672A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company Derivatives of lincosaminide antibiotics
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
WO1992020715A1 (en) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
WO1995005393A2 (en) * 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067776A (en) * 1975-11-25 1978-01-10 Research Foundation Of Children's Hospital Method for differential diagnosis of meningitis with a limulus lysate test
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
ATE111746T1 (de) * 1989-11-15 1994-10-15 Sandoz Ag Polymyxinkonjugate.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088695A2 (de) * 1982-03-09 1983-09-14 Cytogen Corporation Antikörper-Verbindungen
EP0122132A2 (de) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Antikrebsmittel
WO1989004672A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company Derivatives of lincosaminide antibiotics
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
WO1992020715A1 (en) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
WO1995005393A2 (en) * 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALPERT G. ET AL: "Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock" JOURNAL OF INFECTIOUS DISEASES, vol. 165, 1992, pages 494-500, XP002085408 *
BOORSMA D. M. ET AL: "Periodate or glutaraldehyde for preparing peroxidase conjugates?" JOURNAL OF IMMUNOLOGICAL METHODS, vol. 30, 1979, pages 245-255, XP002085409 *
DRABICK JJ ET AL: "Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent." ANTIMICROB AGENTS CHEMOTHER, MAR 1998, 42 (3) P583-8, XP002073819 UNITED STATES *
FISCHER G.W.: "Use of intravenous immune globulin in newborn infants" CLIN. EXP. IMMUNOL. SUPPL., 1994, 97/1 (73-77), XP002073910 United Kingdom *
See also references of WO9414437A1 *

Also Published As

Publication number Publication date
EP0679083A4 (de) 1999-03-24
AU693433B2 (en) 1998-07-02
AU6226994A (en) 1994-07-19
WO1994014437A1 (en) 1994-07-07
CA2151386A1 (en) 1994-07-07
JPH08504824A (ja) 1996-05-28

Similar Documents

Publication Publication Date Title
US5545721A (en) Conjugates for the prevention and treatment of sepsis
US6579696B1 (en) Polymyxin B conjugates
Gough et al. Antiendotoxin activity of cationic peptide antimicrobial agents
US6660267B1 (en) Prevention and treatment of sepsis
JP4656728B2 (ja) ブドウ球菌抗原及びワクチン
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
JP2009227680A (ja) 腸球菌抗原およびワクチン
US5955074A (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
US20190309095A1 (en) Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof
Kirikae et al. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli
AU693433B2 (en) Prevention and treatment of sepsis
US5998381A (en) Compounds that bind bacterial pili
EP0628056A1 (de) Zielgerichtete humane immunglobuline zur verhinderung und behandlung von staphylococcen-infektionen
Doran et al. Influence of clindamycin on fibronectin-staphylococcal interactions
Seelen et al. The anti-lipid A monoclonal antibody E5 binds to rough gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes.
Warren et al. Protective Efficacy of CAP18106–138–Immunoglobulin G in Sepsis
AU6553899A (en) Prevention and treatment of sepsis
Morhart et al. Evaluation of enzyme immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients
JPH05505592A (ja) セプシスの治療用製剤製品
US7053067B2 (en) Chlamydia oligosaccharides
Eckhardt et al. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay
Wolff et al. Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity.
Cuffini et al. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae
Torney et al. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus
Kim et al. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990206

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000315

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROMEGA CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020701